chronic inflammatory disease

PALO ALTO, Calif. and NEW YORK — September 23, 2026 Evommune, Inc. announced that Phase 2a data for EVO301...

PARIS, France, July 30, 2026 Abivax SA announced the successful completion of a positive pre-New Drug Application (pre-NDA) interaction...

INDIANAPOLIS, United States, June 9, 2026 Eli Lilly and Company has secured U.S. Food and Drug Administration (FDA) approval...

HOUSTON, May 22, 2026 FibroBiologics, Inc. announced new preclinical data from its CYPS317 psoriasis program demonstrating durable immune modulation...

Melbourne, Australia – May 15, 2026 Atisama Therapeutics, formerly known as Rage Bio, announced significant progress in the ongoing...

INGELHEIM, Germany and WALTHAM, Mass., May 12, 2026 Boehringer Ingelheim has entered into a global licensing agreement with Immunitas...